Alembic Pharmaceuticals Ltd has received tentative approval from the US Food and Drug Administration for brexpiprazole tablets in 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg and 4 mg strengths, according to an exchange filing.
The drug is a generic version of Otsuka Pharmaceutical Co Ltd's Rexulti tablets.
It is indicated as adjunctive therapy alongside antidepressants for the treatment of major depressive disorders and schizophrenia.
According to information from IQVIA, the drug's sales for the fiscal year that ended in December 2022 totaled about $1.6 billion.
Mumbai Airport Customs Arrest 2 In Separate Cases For Smuggling Drugs Worth ₹20 Crore From Bangkok
IBPS RRB PO Mains Admit Card 2025 Released At ibps.in; Exam On December 28
Gold Hits Record High On Safe-Haven Buying, Rate Cut Hopes & Global Uncertainty
NCERT Forms Team To Develop AI Textbooks For Classes 11 & 12
The shares of the company traded 0.7% higher at ₹515.75 on NSE, at 09:15 IST.
